ContactISSN:e-ISSN: 2757-976X
Author Sign-inReviewer Sign-inRegister
TürkçeEnglish
Home
About Journal
Copyright NoticeOpen Access PolicyAim and ScopePrinciples of ArbitrationReviewer and Editor GuideFee PolicyEthical Principles and Publication PolicyArchiving PolicyIndexing
Information For AuthorsEditorial BoardSend ArticleLatest IssueArchiveContact Us

Effects of sodium glucose co-transporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on blood urea level

YAKUP ÇELİK,MURAT DAĞDEVİREN,DERUN TANER ERTUĞRUL,ESİN BEYAN

  •  Year : 2023
  •  Vol : 3
  •  Issue : 3
  •  Page : 102-108
Aim: Glucagon is known that its secretion increases with the use of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and decreases with the use of dipeptidyl peptidase-4 inhibitor (DPP-4i). Considering the different effects on glucagon, in this study, it was aimed to evaluate the blood urea levels and estimated glomerular filtration rate in patients using these two groups of drugs together.

Methods: 220 patients, 109 in the SGLT2i group and 111 in the DPP4i group, were included in the study. Patients before the start of treatment, after treatment 1-3. month and 4-6. month after treatment blood tests were evaluated retrospectively.

Results: In the SGLT2i group, there was a statistically significant difference in blood urea level, creatinine and estimated glomerular filtration rate between visits 0, 1 and 2. In the DPP-4i group, there was no statistically significant difference in blood urea level and estimated glomerular filtration rate between visits 0, 1 and 2.

Conclusion: It was found that blood urea level increased in patients using SGLT2i, while it did not change in patients using DPP-4i. There is a need for prospective studies that evaluate these drugs as both monotherapy and combination therapy, and also evaluate the interaction of plasma glucagon levels with urea in those using this drug.
Cite this Article As : Çelik Y, Dağdeviren M, Ertuğrul DT, Beyan E. Sodyum Glukoz Ko-Transporter 2 İnhibitörü ve Dipeptidil Peptidaz-4 İnhibitörü İlaçların Kan Üre Düzeyi Üzerine Etkileri. Mev Med Sci. 2023;3(3):102-108

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.
Mevlana Tıp Bilimleri
2023, Vol3, Issue3
E-ISSN: 2757-976X
Received : , Accepted : , Published Online :

References

  1. 1-World Health Organization. Diabetes overview. https://www.who.int/health-topics/diabetes#tab=tab_1(erişim tarihi: 01.01.2023)
  2. 2-Choet NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81.
  3. 3-Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176.
  4. 4- Keri KC, Samji NS, Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect. 2018;8(4):200-207.
  5. 5- Pfeiffer AFH, Klein HH. Therapie des diabetes mellitus typ 2. Dtsch Arztebl Int. 2014;111(5):69–82.
  6. 6-Verma S, Mazer CD, Fitchett D, et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018;61(8):1712-1723.
  7. 7- Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018;138(5):458-468.
  8. 8-Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019;10:389.
  9. 9-Bae JH, Park EG, Kim S, et al. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Sci Rep. 2019;9(1):80–92.
  10. 10- Lin YC, Chang YH, Yang SY, et al. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662-675.
  11. 11- Janah L, Kjeldsen S, Galsgaard KD, et al. Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci. 2019;20(13):3314.
  12. 12-Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(15):1845-1855.
  13. 13-Suga T, Kikuchi O, Kobayashi M, et al. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1-12.
  14. 14-Lundkvist P, Pereira MJ, Kamble PG, et al. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2019;104(1):193-201.
  15. 15-He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51(3):147-162.
  16. 16- Bankir L, Roussel R, Bouby N. Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Renal Physiol. 2015;309(1):F2-F23.
  17. 17-Jian X, Yang QL, Xiao S, et al. The effects of a sodium-glucose cotransporter 2 inhibitor on diabetic nephropathy and serum oxidized low-density lipoprotein levels. Eur Rev Med Pharmacol Sci. 2018;22(12):3994-99.
  18. 18-Sugiyama S, Jinnouchi H, Yoshida A, et al. Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b-4: A real world report from a Japanese Specialized Diabetes Care Center, J Clin Med Res. 2019;11(4):267-74.
  19. 19-Kamel NM, Abd El Fattah MA, El-Abhar HS, Abdallah DM. Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/Enos pathways,” Eur J Pharmacol. 2019;861:172620,
  20. 20-Tonneijck L, Smits MM, Muskit MHA, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in over weight patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2016;39(11):2042-50.
  21. 21-Samocha-Bonet D, Chisholm DJ, Gribble FM, et al. Glycemic effects and safety of L-glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PLoS One. 2014;9(11):e113366
  22. 22-Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087-1095.
  23. 23-Higashikawa T, Ito T, Mizuno T, et al. The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus. J Int Med Res. 2018;46(12):5117-5126.
  24. 24-El Mouhayyar C, Riachy R, Khalil AB, et al. SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review. Int J Endocrinol. 2020;2020:1762164.
  25. 25- Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017;40(1):69-76.
  26. 26- Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610-1619.
  27. 27- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.
  28. 28-Choi SH, Leem J, Lee IK. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice. Mediators Inflamm. 2017;2017:4139439.
  29. 29- Zinman B., Wanner C., Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373 (22):2117–2128.
  30. 30- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657.
  31. 31- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.
  32. 32-Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306.
  33. 33- Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease [published correction appears in Cardiovasc Diabetol. 2018 Mar 9;17 (1):38]. Cardiovasc Diabetol. 2017;16(1):65.
  34. 34- Packer M. Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Am J Nephrol. 2020;51(4):289-293.
  35. 35- Balant LP, Balant-Gorgia EA. Cultural differences: implications on drug therapy and global drug development. Int J Clin Pharmacol Ther. 2000;38(2):47-52.
  36. 36- Ito Y, Ambe K, Hayase T, et al. Comparison of Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter 2 Inhibitors Between Japanese and Non-Japanese Patients: A Meta-Analysis. Clin Transl Sci. 2020;13(3):498-508.
  37. 37- Goh LGH, Sun J, Ong BSK, et al. Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. J Diabetes Metab Disord. 2022;21(1):521-555.
  38. 38- Güven Tezcan S. Temel epidemiyoloji. 1st ed., Ankara, Hipokrat Kitapevi; 2017.